Darinaparsin (trade names Darvias and Zinapar) is a drug for the treatment of various types of cancer. It is an arsenic-containing derivative of glutathione. The mechanism of action of darinaparsin is proposed to involve disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways, thereby inducing cell cycle arrest and apoptosis in cancer cells.<\/p>\n
If darinaparsin injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n","protected":false},"excerpt":{"rendered":"
Darinaparsin, an organoarsenic compound with anticancer activity, is a mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. Darvias (darinaparsin) was approved by the PMDA in Japan in June 2022.<\/p>\n
Disease Indications-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cdarinaparsin injection\u201d based on the information you provide.<\/p>\n
\nManufacturer-Solasia Pharma K.K.
\nUsage-Intravenous
\nMedicine Approved By-Pharmaceuticals and Medical Devices Agency (PMDA) ( no image)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n